Estrella Immunopharma Stock Performance
| ESLAW Stock | 0.09 0 3.53% |
Estrella Immunopharma holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.96, which means possible diversification benefits within a given portfolio. Estrella Immunopharma returns are very sensitive to returns on the market. As the market goes up or down, Estrella Immunopharma is expected to follow. Use Estrella Immunopharma value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Estrella Immunopharma.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Estrella Immunopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Estrella Immunopharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.5 M |
Estrella |
Estrella Immunopharma Relative Risk vs. Return Landscape
If you would invest 10.00 in Estrella Immunopharma on September 3, 2024 and sell it today you would lose (0.90) from holding Estrella Immunopharma or give up 9.0% of portfolio value over 90 days. Estrella Immunopharma is currently producing 5.2589% returns and takes up 38.7439% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Estrella, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Estrella Immunopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Estrella Immunopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Estrella Immunopharma, and traders can use it to determine the average amount a Estrella Immunopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1357
| Best Portfolio | Best Equity | ESLAW | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 38.74 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Estrella Immunopharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Estrella Immunopharma by adding it to a well-diversified portfolio.
Estrella Immunopharma Fundamentals Growth
Estrella Stock prices reflect investors' perceptions of the future prospects and financial health of Estrella Immunopharma, and Estrella Immunopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Estrella Stock performance.
| Return On Asset | -1.75 | ||||
| EBITDA | (7.31 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | (2.89) X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) | ||||
| Working Capital | 4.27 M | ||||
About Estrella Immunopharma Performance
Evaluating Estrella Immunopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Estrella Immunopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Estrella Immunopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.64) | (0.10) | |
| Return On Capital Employed | (1.71) | (0.18) | |
| Return On Assets | (1.64) | (0.10) | |
| Return On Equity | (1.71) | (0.14) |
Things to note about Estrella Immunopharma performance evaluation
Checking the ongoing alerts about Estrella Immunopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Estrella Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Estrella Immunopharma is not yet fully synchronised with the market data | |
| Estrella Immunopharma is way too risky over 90 days horizon | |
| Estrella Immunopharma has some characteristics of a very speculative penny stock | |
| Estrella Immunopharma appears to be risky and price may revert if volatility continues | |
| Estrella Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Estrella Immunopharma faces Nasdaq delisting over equity shortfall |
- Analyzing Estrella Immunopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Estrella Immunopharma's stock is overvalued or undervalued compared to its peers.
- Examining Estrella Immunopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Estrella Immunopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Estrella Immunopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Estrella Immunopharma's stock. These opinions can provide insight into Estrella Immunopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.